Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | PPARD | Q03181 | 3/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7949002 | 0.78 | SMN1; SMN2 (0.56) | SMN1; SMN2KDM4ETDP1ALOX15MAPT | |
| SCHEMBL20587925 | 0.77 | SMN1; SMN2 (0.68) | SMN1; SMN2KDM4ETDP1ALOX15MAPT | |
| SCHEMBL7568303 | 0.77 | SMN1; SMN2 (0.55) | SMN1; SMN2PTGS2KDM4ETDP1ALOX15 | |
| SCHEMBL7948483 | 0.73 | PSMB8 (0.56) | SMN1; SMN2ALOX15MAPTPSMB5 | |
| SCHEMBL15898829 | 0.73 | TP53 (0.38) | SMN1; SMN2TP53KDM4E | |
| Hydrochloric Acid SCHEMBL10671160 | 0.72 | PSMB8 (0.55) | SMN1; SMN2ALOX15MAPTPSMB5 | |
| SCHEMBL187791 | 0.72 | POLQ (0.61) | PTGS2KDM4ETDP1AKR1B1 | |
| SCHEMBL29718585 | 0.72 | POLQ (0.61) | PTGS2KDM4ETDP1AKR1B1 | |
| SCHEMBL29525642 | 0.71 | PTGS2 (0.57) | PTGS2TDP1AKR1B1 | |
| SCHEMBL30428048 | 0.71 | PTGS2 (0.54) | PTGS2KDM4ETDP1MAPTAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2289868-B1 | CARBOXYLIC ACID COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2014-08-13 | — | — | EP | disclosed |
| US-8222281-B2 | Carboxylic acid compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20110053974-A1 | CARBOXYLIC ACID COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2289868-A1 | CARBOXYLIC ACID COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2011-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053974-A1 | CARBOXYLIC ACID COMPOUND | AKR1C3, SLC5A1, GPR119 | SMN1; SMN2 3695/4885TP53 2630/4885PTGS2 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.